Thomas Heineman Purchases 15,000 Shares of Oncolytics Biotech Inc. (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) Senior Officer Thomas Heineman purchased 15,000 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The stock was bought at an average cost of C$1.74 per share, for a total transaction of C$26,098.50.

Oncolytics Biotech Trading Down 0.6%

Shares of ONC traded down C$0.01 on Monday, reaching C$1.72. 146,504 shares of the company's stock were exchanged, compared to its average volume of 147,154. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The stock has a market capitalization of C$132.57 million, a P/E ratio of -4.79 and a beta of 1.35. The business has a 50 day moving average price of C$0.92 and a two-hundred day moving average price of C$0.94. Oncolytics Biotech Inc. has a 12 month low of C$0.44 and a 12 month high of C$2.08.

Analyst Ratings Changes

Separately, Jones Trading lowered Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.